You are on page 1of 2

Growing In Vitro Diagnostics (IVD) Market to Set New Business Opportunities

for Start Up Company

Vidan Diagnostics Expected to Provide Access to Unique Tests Related to Monitoring of Diabetes
and Sepis.

San Antonio, TX, April 05, 2018 --(PR.com)-- Today Vidan Diagnostics, LLC announces it has
officially started business operations in the United States. Vidan Diagnostics also announced with
business launching early this year, healthcare professionals will have access to Vidan's new products
through its national distributors in the coming weeks.

The First of Many Unique Tests


Vidan will introduce the Lucidplus™ β-Ketone Plus Glucose Monitoring System during the second
quarter. The availability of the Lucidplus™ and the diminished usage of urine-based (nitroprusside)
ketone tests will further spur the acceptance of beta-hydroxybutyrate testing as the preferred method for
monitoring patients with diabetic ketoacidosis, (DKA). Diabetic ketoacidosis is a complication of
diabetes that occurs when ketones build up in the bloodstream. “Having new and innovative products like
the Lucidplus™ is critical to the success of our new company,” said Gilbert Mejia, CEO of Vidan
Diagnostics. “We are fortunate to have developed a healthy product pipeline for diabetes and sepsis tests
that will benefit patients and healthcare providers,” added Mr. Mejia.

Founded in 2015, Vidan Diagnostics LLC is a supplier of medical diagnostic products. It is focused on
medical devices and reagents used for diagnosing and monitoring patients with conditions of diabetes,
sepsis, anemia, heart disease and stroke. Vidan Diagnostics is dedicated to delivering proven and
innovative products to all people in all places, in all aspects and stages of life with integrity and
reliability. The company is headquartered in San Antonio, Texas.

Page 1/2
PR.com Press Release Distribution Terms of Use
Contact Information:
Vidan Diagnostics, LLC
Gilbert Mejia
(800) 869-5992
Contact via Email
www.vidandiagnostics.com

Online Version of Press Release:


You can read the online version of this press release at: https://www.pr.com/press-release/749771

Page 2/2
PR.com Press Release Distribution Terms of Use

You might also like